Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment

Figures & data

Figure 1 Sample selection.

Table 1 Antiretroviral Regimens Of Interest

Select Single-Tablet Regimens (STRs)^a
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate	EVG/COBI/FTC/TAF	1991
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate	EVG/COBI/FTC/TDF	2526
Abacavir/lamivudine/dolutegravir	ABC/3TC/DTG	2585
Efavirenz/emtricitabine/tenofovir disoproxil fumarate	EFV/FTC/TDF	2183
Select Multi-Tablet Regimens (MTRs)^a
Emtricitabine/tenofovir disoproxil fumarate + dolutegravir	FTC/TDF+DTG	932
Emtricitabine/tenofovir disoproxil fumarate + boosted darunavir^b	FTC/TDF+DRV/r or c	1011
Emtricitabine/tenofovir disoproxil fumarate + boosted atazanavir^c	FTC/TDF+ATV/r or c	447

Notes: ^aPatients indexed on rilpivirine/emtricitabine/tenofovir disoproxil fumarate (n=1264), rilpivirine/emtricitabine/tenofovir alafenamide fumarate (N=74), emtricitabine/tenofovir alafenamide fumarate + dolutegravir (N=9), abacavir/lamivudine + boosted darunavir (n=100), emtricitabine/tenofovir alafenamide fumarate + boosted darunavir (N=4), and emtricitabine/tenofovir alafenamide fumarate + boosted atazanavir (N=1) were included in the sample selection and the overall STR and MTR evaluations, but were not evaluated by regimen; ^bBoosted with ritonavir or cobicistat. Cobicistat boosted agent includes the darunavir+cobicistat combination pill Prezcobix as well as the individual drugs; ^cBoosted with ritonavir or cobicistat. Cobicistat boosted agent includes the atazanavir+cobicistat combination pill Evotaz as well as the individual drugs.

Table 2 Baseline Demographic And Clinical Characteristics

	Total		STR		MTR
Characteristic	N = 13,127		N=10,623		N=2504
Age, mean (SD) [median]	42.8 (12.9) [43.0]		42.6 (13.0) [43.0]		43.8 (12.4) [45.0]
18–34 years	4040	30.8%	3385	31.9%	655	26.2%
35–49 years	4772	36.4%	3797	35.7%	975	38.9%
50–64 years	3707	28.2%	2938	27.7%	769	30.7%
≥65 years	608	4.6%	503	4.7%	105	4.2%
Gender
Male	9978	76.0%	8247	77.6%	1731	69.1%
Female	3149	24.0%	2376	22.4%	773	30.9%
Geographic Region
Northeast	2167	16.5%	1738	16.4%	429	17.1%
Midwest	1996	15.2%	1601	15.1%	395	15.8%
South	6879	52.4%	5625	53.0%	1254	50.1%
West	2085	15.9%	1659	15.6%	426	17.0%
Insurance Type
Cash	714	5.4%	591	5.6%	123	4.9%
Commercial	9658	73.6%	7957	74.9%	1701	67.9%
Medicare	1261	9.6%	936	8.8%	325	13.0%
Medicaid	1492	11.4%	1138	10.7%	354	14.1%
Unknown	2	0.0%	1	0.0%	1	0.0%
Pre-index medication use
Antibiotics	4936	37.6%	4008	37.7%	928	37.1%
Antihypertensives	2382	18.2%	1928	18.2%	454	18.1%
Antidiabetics	645	4.9%	532	5.0%	113	4.5%
Lipid-lowering therapy	985	7.5%	826	7.8%	159	6.4%
Anticoagulants	406	3.1%	326	3.1%	80	3.2%
Respiratory drugs^a	425	3.2%	340	3.2%	85	3.4%
Patients with ≥1 non-ART drugs on index date	3723	28.4%	2746	25.9%	977	39.0%
Post-index observation days^b mean (SD) [median]	457.5 (34.8) [458.0]		457.7 (34.8) [458.0]		457.0 (34.8) [458.0]

Notes: ^aIncludes lower and upper respiratory infections; ^bMeasured as number of days from index date until the end of study period.

Abbreviations: STR, single-tablet regimen; MTR, multi-tablet regimen.

Figure 2 Proportion of adherent patients by 30-day Intervals: STR vs MTR ART regimens (A) and ART Regimen (B).

Figure 3 Time to discontinuation for STR vs MTR ART regimens (A) and among select ART regimens (B).

Figure 4 Adjusted* hazard ratios for select treatment discontinuation. *Each model was adjusted for age group, gender, geographic region, insurance type, baseline medications, and number of unique prescriptions on index date.